Also known as Ozempic, Wegovy, Rybelsus
GLP-1 receptor agonist approved in the United States for specific diabetes and weight-management indications, depending on product and labeling.
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist. FDA-approved products include injectable and oral presentations with indication-specific labeling. Research and labeling also address cardiovascular and, for some presentations, other outcome claims that must be read from the current official label rather than inferred from brand conversation.
Semaglutide is a laboratory-made peptide designed to activate the GLP-1 receptor, a receptor involved in insulin secretion, glucagon suppression, gastric emptying, and appetite signaling.
It is not a generic 'weight-loss peptide' in the research-chemical sense. It is an approved prescription medicine in defined products, with boxed warnings and contraindications that appear in FDA labeling.
Different brand products are not interchangeable by nickname. Indication, dose presentation, and safety language are product-specific.
Semaglutide copies some of the actions of the gut hormone GLP-1. After meals, GLP-1 signaling can help the pancreas release insulin when glucose is high, lower glucagon, slow stomach emptying, and change appetite signals in the brain. The medicine is built to last longer in the body than natural GLP-1.
As a GLP-1 receptor agonist, semaglutide engages Gs-coupled GLP-1 receptors on pancreatic beta cells and other tissues, increasing cAMP and glucose-dependent insulin secretion. Additional effects include reduced glucagon, delayed gastric emptying, and central appetite-circuit modulation. Albumin binding and amino-acid substitutions extend half-life relative to native GLP-1, enabling weekly injectable regimens for some products. Official pharmacology sections of labeling remain the primary reference.
Step 1
Peptide
Semaglutide (GLP-1 receptor agonist)
Step 2
Target
GLP-1 receptor (multiple tissues, including pancreas and CNS pathways)
Step 3
Pathway
Glucose-dependent insulin secretion, glucagon suppression, gastric emptying, appetite signaling
Step 4
Observed in research/labeling
Glycemic and weight-related effects in indicated populations; CV outcome data for specific labeled uses
Injectable semaglutide products such as Ozempic are labeled as GLP-1 receptor agonists used with diet and exercise to improve glycemic control in adults with type 2 diabetes, among other labeled claims that must be read from the current DailyMed label.
Wegovy labeling describes semaglutide as a GLP-1 receptor agonist for indicated weight-management uses. Trial evidence such as STEP 1 informs that indication; it is not a do-it-yourself protocol.
Ozempic labeling includes reduction of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease. SUSTAIN-6 is a key supporting trial.
Large randomized outcome and metabolic trials exist, including cardiovascular outcome work and obesity trials for specific regimens. Approved use is defined by labeling, not by internet summaries.
Rodent thyroid C-cell tumor findings are described in labeling and inform boxed-warning language. Human relevance of those animal findings has not been determined, per FDA labeling.
2016 · Human clinical trial
Population: Adults with type 2 diabetes at high cardiovascular risk
Objective: Evaluate the effect of once-weekly semaglutide on major adverse cardiovascular events compared with placebo, on a background of standard care.
Main finding: The trial reported a lower rate of the primary composite cardiovascular outcome with semaglutide than with placebo in the studied population. Labeling should be used for current approved indications.
Limitations: Trial populations, background therapy, and follow-up duration limit generalization beyond the studied indication and eligibility criteria.
2021 · Human clinical trial
Population: Adults with overweight or obesity without diabetes in the primary analysis population
Objective: Assess body-weight change with once-weekly semaglutide 2.4 mg plus lifestyle intervention versus placebo.
Main finding: The trial reported greater mean weight reduction with semaglutide than placebo in the studied population. This is clinical trial evidence for a specific regimen, not personalized dosing advice.
Limitations: Lifestyle co-intervention, selected eligibility, and treatment duration affect interpretation. Adverse-effect profiles require the full paper and labeling.
2021 · Human clinical trial
Population: Adults with type 2 diabetes
Objective: Compare glycemic and related outcomes with tirzepatide versus semaglutide 1 mg once weekly.
Main finding: The trial reported greater reductions in glycated hemoglobin with tirzepatide than with the semaglutide comparator used in the study. Cross-trial or off-label comparisons should not be inferred.
Limitations: Comparator dose, open-label or design features as reported in the paper, and population limits apply. Not a ranking of all peptides.
Safety information may be incomplete, especially for experimental peptides.
Safety information may be incomplete, especially for experimental peptides. Consult a qualified healthcare professional for personal medical advice. For approved semaglutide products, the FDA label is the safety source of record.
Long-term safety: Outcome trials exist for specific populations and products. Residual uncertainty remains for uses and durations outside those programs.
Evidence limitations: Internet discussions often mix products, doses, and compounding. Only licensed labeling defines approved use.
Administration practices vary by compound and clinical context. Follow approved prescribing information or guidance from a qualified healthcare professional. This page does not provide injection technique, mixing, or personalized dosing instructions.
Approved prescribing information
Dosing, titration, missed-dose rules, and device instructions are defined in the product label (for example Ozempic or Wegovy DailyMed entries). This platform does not convert those tables into personal advice.
Discovery / analog design
complete
GLP-1 analog development preceding approved products.
Preclinical research
complete
Includes rodent C-cell findings described in labeling.
Human studies
complete
Extensive phase 2/3 programs.
Clinical trials
complete · 2016–2021+
SUSTAIN, STEP, and other programs.
Regulatory status
complete · 2017+
Initial U.S. approval 2017; additional products and indications thereafter.
It is a GLP-1 receptor agonist used in FDA-approved prescription products for specific indications. Product names and labels are not interchangeable.
Depending on product, labeling includes type 2 diabetes glycemic control, selected cardiovascular risk reduction, and chronic weight management, among other labeled claims. Read the current label.
It activates GLP-1 receptors involved in glucose-dependent insulin secretion, glucagon, gastric emptying, and appetite pathways.
Multiple large human trials support labeled uses. That is not the same as safety or benefit for unlabeled or compounded products.
Yes, as specific prescription products. Approval is indication- and product-specific.
Labeling includes a boxed warning related to rodent thyroid C-cell tumors, gastrointestinal effects, pancreatitis warnings, and other precautions. This is not a complete list.
Metabolic Research
Dual GIP and GLP-1 receptor agonist approved in the United States for specific diabetes and weight-related indications, depending on product labeling.
View peptide →